In spite of the progress in the treatment of non-small-cell lung cancer (NSCLC), the majority of patients with advanced disease still receive chemotherapy. Gemcitabine alone or combined with a platinum compound is a valid option. Thrombocytosis is a recognized prognostic factor in lung cancer and an adverse event that may occur during gemcitabine infusion.
We retrospectively evaluated all patients with NSCLC treated with first-line gemcitabine-based chemotherapy in two Italian hospitals. We assessed the onset of thrombocytosis within the third cycle of therapy and the relation between thrombocytosis and survival.
We included 318 patients. Thrombocytosis occurred in 156 patients (49.1%). Median progression-free survival (PFS) was 5.6 months (95% CI, 4.7-6.9 months) in patients who developed thrombocytosis versus 6 months (95% CI, 5.1-7.2 months) in patients without thrombocytosis (p = 0.21). Median overall survival (OS) was 11.2 months (95% CI, 9.8-13.4 months) in patients with thrombocytosis versus 12 months (95% CI, 10.1-14.4 months) in patients without thrombocytosis (p = 0.25). We observed no difference in terms of PFS or OS according to age, sex, stage, chemotherapy (single-agent versus combination chemotherapy) and thrombocytosis.
Thrombocytosis is neither a prognostic nor a predictive factor for PFS or OS in patients with advanced NSCLC treated with first-line gemcitabine-based chemotherapy.
Tumori 2017; 103(2): 143 - 147
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsStefania Canova, Federica Cicchiello, Francesco Agustoni, Giampaolo Bianchini, Maria Ida Abbate, Paolo Bidoli, Diego Luigi Cortinovis
- • Accepted on 25/10/2016
- • Available online on 28/11/2016
- • Published in print on 24/03/2017
This article is available as full text PDF.
- Canova, Stefania [PubMed] [Google Scholar] 1, * Corresponding Author (email@example.com)
- Cicchiello, Federica [PubMed] [Google Scholar] 1
- Agustoni, Francesco [PubMed] [Google Scholar] 2
- Bianchini, Giampaolo [PubMed] [Google Scholar] 3
- Abbate, Maria Ida [PubMed] [Google Scholar] 1
- Bidoli, Paolo [PubMed] [Google Scholar] 1
- Cortinovis, Diego Luigi [PubMed] [Google Scholar] 1
Department of Medical Oncology, San Gerardo Hospital, Monza - Italy
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - Italy
Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan - Italy
Stefania Canova and Federica Cicchiello contributed equally to this work.